MPT0B291

MPT0B291 is a selective small molecule inhibitor of histone deacetylases (HDAC), specifically targeting HDAC1, HDAC2, and HDAC6. Developed by researchers at Taipei Medical University and the National Health Research Institutes in Taiwan, it has been investigated for its potential to treat temozolomide (TMZ)-resistant glioblastoma. The compound works by inhibiting the deacetylation of the transcription factor Sp1, which in turn suppresses the expression of anti-senescence and stemness-related genes such as hTERT and BMI1. By modulating these epigenetic pathways, MPT0B291 sensitizes glioblastoma cells to chemotherapy and induces cellular senescence, offering a potential strategy to overcome acquired drug resistance in brain tumors.